Cargando…

Non-canonical PD-1 signaling in cancer and its potential implications in clinic

Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally con...

Descripción completa

Detalles Bibliográficos
Autores principales: Zha, Haoran, Jiang, Ying, Wang, Xi, Shang, Jin, Wang, Ning, Yu, Lei, Zhao, Wei, Li, Zhihua, An, Juan, Zhang, Xiaochun, Chen, Huoming, Zhu, Bo, Li, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888367/
https://www.ncbi.nlm.nih.gov/pubmed/33593825
http://dx.doi.org/10.1136/jitc-2020-001230
_version_ 1783652147502514176
author Zha, Haoran
Jiang, Ying
Wang, Xi
Shang, Jin
Wang, Ning
Yu, Lei
Zhao, Wei
Li, Zhihua
An, Juan
Zhang, Xiaochun
Chen, Huoming
Zhu, Bo
Li, Zhaoxia
author_facet Zha, Haoran
Jiang, Ying
Wang, Xi
Shang, Jin
Wang, Ning
Yu, Lei
Zhao, Wei
Li, Zhihua
An, Juan
Zhang, Xiaochun
Chen, Huoming
Zhu, Bo
Li, Zhaoxia
author_sort Zha, Haoran
collection PubMed
description Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally considered to be the primary source of PD-1 in cancer, accumulating evidence suggests that other distinct cell types, including B cells, regulatory T cells, natural killer cells, dendritic cells, tumor-associated macrophages and cancer cells, also express PD-1. Hence, the response of patients with cancer to PD-1 blockade therapy is a cumulative effect of anti-PD-1 antibodies acting on a myriad of cell types. Although, the contribution of CD8 T cells to PD-1 blockade therapy has been well-established, recent studies also suggest the involvement of non-canonical PD-1 signaling in blockade therapy. This review discusses the role of non-canonical PD-1 signaling in distinct cell types and explores how the available knowledge can improve PD-1 blockade immunotherapy, particularly in identifying novel biomarkers and combination treatment strategies.
format Online
Article
Text
id pubmed-7888367
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78883672021-03-03 Non-canonical PD-1 signaling in cancer and its potential implications in clinic Zha, Haoran Jiang, Ying Wang, Xi Shang, Jin Wang, Ning Yu, Lei Zhao, Wei Li, Zhihua An, Juan Zhang, Xiaochun Chen, Huoming Zhu, Bo Li, Zhaoxia J Immunother Cancer Review Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally considered to be the primary source of PD-1 in cancer, accumulating evidence suggests that other distinct cell types, including B cells, regulatory T cells, natural killer cells, dendritic cells, tumor-associated macrophages and cancer cells, also express PD-1. Hence, the response of patients with cancer to PD-1 blockade therapy is a cumulative effect of anti-PD-1 antibodies acting on a myriad of cell types. Although, the contribution of CD8 T cells to PD-1 blockade therapy has been well-established, recent studies also suggest the involvement of non-canonical PD-1 signaling in blockade therapy. This review discusses the role of non-canonical PD-1 signaling in distinct cell types and explores how the available knowledge can improve PD-1 blockade immunotherapy, particularly in identifying novel biomarkers and combination treatment strategies. BMJ Publishing Group 2021-02-16 /pmc/articles/PMC7888367/ /pubmed/33593825 http://dx.doi.org/10.1136/jitc-2020-001230 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Zha, Haoran
Jiang, Ying
Wang, Xi
Shang, Jin
Wang, Ning
Yu, Lei
Zhao, Wei
Li, Zhihua
An, Juan
Zhang, Xiaochun
Chen, Huoming
Zhu, Bo
Li, Zhaoxia
Non-canonical PD-1 signaling in cancer and its potential implications in clinic
title Non-canonical PD-1 signaling in cancer and its potential implications in clinic
title_full Non-canonical PD-1 signaling in cancer and its potential implications in clinic
title_fullStr Non-canonical PD-1 signaling in cancer and its potential implications in clinic
title_full_unstemmed Non-canonical PD-1 signaling in cancer and its potential implications in clinic
title_short Non-canonical PD-1 signaling in cancer and its potential implications in clinic
title_sort non-canonical pd-1 signaling in cancer and its potential implications in clinic
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888367/
https://www.ncbi.nlm.nih.gov/pubmed/33593825
http://dx.doi.org/10.1136/jitc-2020-001230
work_keys_str_mv AT zhahaoran noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT jiangying noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT wangxi noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT shangjin noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT wangning noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT yulei noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT zhaowei noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT lizhihua noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT anjuan noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT zhangxiaochun noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT chenhuoming noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT zhubo noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic
AT lizhaoxia noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic